What is the interpretation of a 35-year-old female's day 3 fertility test results showing Estradiol (E2) at 24.8 pg/mL, Luteinizing hormone (LH) at 4.06 mIU/mL, Follicle Stimulating Hormone (FSH) at 6.04 mIU/mL, and Progesterone (P4) at 0.281 ng/mL?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 20, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Day 3 Fertility Test Interpretation

These day 3 hormone results indicate normal ovarian reserve and excellent reproductive potential for a 35-year-old woman, with all values falling within optimal ranges for fertility.

FSH Assessment

The FSH level of 6.04 mIU/mL is excellent and indicates normal ovarian reserve. 1, 2

  • In women of peak reproductive age (20-25 years), the day 3 FSH geometric mean is 5.6 IU/L with an upper limit of 9.5 IU/L 3
  • For women aged 40-45 years, the geometric mean rises to 9.6 IU/L (95% CI: 3.8-23.8 IU/L) 3
  • FSH levels <15 mIU/mL are associated with the highest pregnancy rates in IVF (17.0% per attempt), compared to moderate levels (15-24.9 mIU/mL) at 9.3% and high levels (>25 mIU/mL) at only 3.6% 4
  • This patient's FSH of 6.04 mIU/mL places her in the optimal prognostic category 4

Estradiol (E2) Assessment

The E2 level of 24.8 pg/mL is ideal and within the normal baseline range. 1, 2

  • In women aged 20-25 years, day 3 E2 geometric mean is 44.0 pg/mL (95% CI: 20.4-95.0 pg/mL) 3
  • Elevated day 3 E2 (≥80 pg/mL) is associated with lower pregnancy rates (14.8% vs 37.0%) and higher IVF cancellation rates (18.5% vs 0.4%), even when FSH is normal 5
  • When day 3 E2 reaches ≥100 pg/mL, there is a 33.3% cancellation rate with no pregnancies achieved 5
  • This patient's E2 of 24.8 pg/mL is well below any concerning threshold and indicates excellent ovarian responsiveness 5

LH Assessment

The LH level of 4.06 mIU/mL is normal for early follicular phase. 2

  • Normal follicular phase LH ranges from approximately 4.78-13.2 IU/L 6
  • An LH:FSH ratio >2 suggests PCOS and likely anovulation 2
  • This patient's LH:FSH ratio is 0.67 (4.06/6.04), which is normal and excludes PCOS 2
  • LH <7 IU/mL may indicate hypothalamic dysfunction, but in the context of normal FSH and E2, this LH level is appropriate for early follicular phase 2

Progesterone Assessment

The progesterone level of 0.281 ng/mL is appropriately low for day 3, confirming proper cycle timing. 1

  • Day 3 progesterone should be at baseline levels (typically <1 ng/mL in early follicular phase) 6
  • Mid-luteal progesterone ≥5 ng/mL (≥16 nmol/L) confirms ovulation occurred, while levels <5 ng/mL may indicate anovulation 1
  • This baseline level is expected on day 3 and does not indicate any dysfunction 1

Clinical Implications and Next Steps

This hormone profile indicates normal ovarian reserve with excellent fertility potential. 3, 4, 5

  • All parameters fall within optimal ranges for reproductive success 3, 4, 5
  • If evaluating ovulation, a mid-luteal progesterone measurement (approximately day 21 in a 28-day cycle, or 7 days before expected menses) should be obtained to confirm ovulation 1
  • For irregular cycles, timing should be adjusted to approximately 7 days before expected menses rather than using calendar day 21 1

Important Caveats

  • In women aged 40-45 years, 22% show normal day 3 FSH and E2 in one cycle but elevated values in a consecutive cycle, so a single normal result may not fully represent ovarian reserve 3
  • If fertility concerns persist despite normal testing, consider repeating day 3 hormones in a subsequent cycle to confirm consistency 3
  • Anti-Müllerian hormone (AMH) testing can provide additional information about ovarian reserve without cycle-day dependency 2

References

Guideline

Day 21 Progesterone Level as an Indicator of Ovulation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Hormonal Indicators of Ovulation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.